Wednesday, September 02, 2020 02:22 PM

ACTIVE SURVEILLANCE FOR PROSTATE CANCER CAN BE INDIVIDUALIZED BASED ON RISK PARAMETERS - UROLOGY TIMES

The intensity level of active surveillance for a man with low-risk prostate cancer can be personalized based on his individual risk factors, according to research published in JAMA Oncology.1

Active surveillance as currently practiced and currently described in most of the guidelines involves a combination of periodic PSA assessments and tumor assessments. And classically, the tumor assessments have all required prostate biopsy on a regular basis. Initially, it was every year; most guidelines now say every 1 to 2 years. And that timing is what we are now really trying to tailor, lead researcher Matthew R. Cooperberg, MD, said in an interview with JAMA Oncology made simultaneously available with the publication.2

The frequency of the biopsies in particular in active surveillance is a concern. Every time we do a biopsy of the prostate, there is discomfort, there is risk of bleeding and there's a low risk of a significant infection. Patients don't like them, they're expensive, and they're not without risk. So there's been a lot of interest in alternatives to biopsy. MRI has not yet been shown to be a safe replacement for biopsy; [although] it can help guide the decision in some select cases. And it's a combination of the ...

News source: GOOGLE NEWS

See also: The Robotic Urologist